Standard BioTools (NASDAQ:LAB – Get Rating) and Pacific Biosciences of California (NASDAQ:PACB – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.
Profitability
This table compares Standard BioTools and Pacific Biosciences of California's net margins, return on equity and return on assets.
Get
Standard BioTools alerts:
| Net Margins | Return on Equity | Return on Assets |
| Standard BioTools | -163.64% | -2,049.96% | -24.12% |
| Pacific Biosciences of California | -218.44% | -42.03% | -15.59% |
Analyst Recommendations
This is a summary of current recommendations for Standard BioTools and Pacific Biosciences of California, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Standard BioTools | 0 | 0 | 0 | 0 | N/A |
| Pacific Biosciences of California | 0 | 3 | 3 | 0 | 2.50 |
Pacific Biosciences of California has a consensus price target of $15.71, suggesting a potential upside of 35.70%. Given Pacific Biosciences of California's higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Standard BioTools.
Insider & Institutional Ownership
63.2% of Standard BioTools shares are owned by institutional investors. Comparatively, 92.9% of Pacific Biosciences of California shares are owned by institutional investors. 51.6% of Standard BioTools shares are owned by insiders. Comparatively, 1.4% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Standard BioTools and Pacific Biosciences of California's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Standard BioTools | $109.19 million | 1.51 | -$59.24 million | ($2.30) | -0.90 |
| Pacific Biosciences of California | $130.51 million | 20.06 | -$181.22 million | ($1.34) | -8.64 |
Standard BioTools has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Standard BioTools has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.
Summary
Pacific Biosciences of California beats Standard BioTools on 9 of the 13 factors compared between the two stocks.
About Standard BioTools
(Get Rating)
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
About Pacific Biosciences of California
(Get Rating)
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.
